· SME · NSE
Price Band
₹132–139
Lot Size
1000 shares
Issue Size
₹52 Cr
Min. Investment
₹1,39,000
Indicative, updates through the day
Cap price plus current GMP: ₹139 — arithmetic, not a forecast
Subscription data will appear once bidding opens.
Bio Medica Laboratories IPO is an SME issue that listed on NSE on 29 May 2026. The issue price band is fixed at ₹132–₹139 per equity share with a minimum market lot size of 1000 shares, bringing the total issue size to ₹52 Cr. At the upper price band, the minimum retail application requires one lot amounting to ₹1,39,000.
No meaningful grey market premium is actively quoted for Bio Medica Laboratories IPO at this stage. For an SME issue at this point in the timeline, this is standard until anchor book allocations and institutional bids build volume. A missing premium is not negative sentiment; it reflects lower off-market liquidity. Read our complete guide to IPO GMP mechanics.
The minimum investment for retail investors is one lot of 1000 shares (approx. ₹1,39,000 at the cut-off price). Applications must be submitted using ASBA via Net Banking or the UPI Mandate route through registered stockbrokers (Zerodha, Groww, Angel One, Upstox).
The official registrar appointed for this issue is Skyline Financial Services Pvt. Ltd., with the basis of allotment finalised on 26 May 2026 and listing completed on 29 May 2026. Once declared, you can check your allotment status on our IPO Allotment Checker using your PAN or Application Number. If you are not allotted shares, the ASBA block on your bank funds is automatically released by T+2 day.
Issue Price
₹139
Listed At
₹111.2
Current Price
₹115.8
Incorporated in August 2015, Bio Medica Laboratories specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the-counter (OTC) medications in liquid and dry-powder injectable forms.der injectables. These injectables are available in both single-dose and multi-dose formats, serving the needs of both human and veterinary healthcare. It offers comprehensive range of products, including generic drugs, branded pharmaceuticals, over the counter (OTC) products, and other medications. The company operates on a B2B model, focusing exclusively on contract manufacturing. It develop formulations for various companies in accordance with their specific requirements and product specifications. It is certified for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certificate issued by the Food & Drugs Administration, Madhya Pradesh. It has two manufacturing facilities in Indore, Madhya Pradesh.
| Category | Shares Offered | % |
|---|---|---|
| QIB | 36,000 | 1% |
| NII (HNI) | 17,55,000 | 48.98% |
| − bNII > ₹10L | 11,70,000 | 0% |
| − sNII < ₹10L | 5,85,000 | 0% |
| Retail | 17,92,000 | 50.01% |
| Market Maker | 1,89,000 | 0% |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 2000 | ₹2,78,000 |
| Individual investors (IND) (Max) | 2 | 2000 | ₹2,78,000 |
| S-HNI (Min) | 3 | 3000 | ₹4,17,000 |
| S-HNI (Max) | 7 | 7000 | ₹9,73,000 |
| B-HNI (Min) | 8 | 8000 | ₹11,12,000 |
EPS (Pre IPO)
10.67
EPS (Post IPO)
10.33
ROE
54.41%
P/E (Pre IPO)
13.03
P/E (Post IPO)
13.45
Price / Book
Market Cap
₹128Cr.
| Company | P/E | ROE | Revenue |
|---|---|---|---|
| Goldline Pharmaceutical Ltd. | 10.47 | ₹11.61 Cr | |
| Speciality Medicines Ltd. | 9.27 | ₹29.14 Cr | |
| Accretion Nutraveda Ltd. | 26.27 | ₹24.77 Cr | |
| KRM Ayurveda Ltd. | 17.32 | ₹77.49 Cr | |
| Curis Lifesciences Ltd. | 12.44 | ₹27.52 Cr | |
| Aptus Pharma Ltd. | 11.29 | ₹13.02 Cr |
Bio Medica Laboratories Ltd. Address
Skyline Financial Services Pvt. Ltd.